What is the difference between Pramiracetam and Unifiram?

Pramiracetam: Pramiracetam is a non-peptide synthetic racetam-class nootropic (2-oxopyrrolidone/pyrrolidinone acetamide derivative) with CAS 68497-62-1 and molecular formula C14H27N3O2. It was previously approved a... Unifiram: Unifiram (DM-232) is a synthetic non-peptide small-molecule nootropic structurally related to sunifiram, though not a racetam itself. It originated from Italian academic research (University of Floren...

What does the research say about Pramiracetam vs Unifiram?

Pramiracetam: Human data consist of a handful of small older trials (1985–1996): healthy-volunteer pharmacokinetic studies, a scopolamine-induced-amnesia challenge study, a placebo-controlled trial in young males with head-injury/anoxia-related memory deficits (400 mg TID improved delayed recall), and a small dose-finding trial in Alzheimer's disease that found… Unifiram: No human data of any kind exist for unifiram; no registered clinical trials or published human studies were found. All available evidence is from rodent behavioral and in-vitro electrophysiology studies. In mice and rats, unifiram (0.001–1 mg/kg i.p. or 0.01–0.1 mg/kg oral) reversed amnesia induced by scopolamine, mecamylamine, baclofen, clonidine,…

Pramiracetam vs Unifiram

Q: Can you stack Pramiracetam and Unifiram?

Pramiracetam (cognitive) and Unifiram (cognitive) are in the same category and may have overlapping mechanisms — researchers should review both profiles carefully before combining. Consult a licensed provider before combining any compounds.

Head-to-head comparison of Pramiracetam and Unifiram — mechanism, side effects, legal status, and pricing.

Pramiracetam

Pramiracetam is a non-peptide synthetic racetam-class nootropic (2-oxopyrrolidone/pyrrolidinone acetamide derivative) with CAS 68497-62-1 and molecular formula C14H27N3O2. It was previously approved and marketed in Italy and some Eastern European countries under brand names Pramistar, Neupramir, and Remen for memory/attention deficits in aging-associated dementias; Italian authorization was revoked in 2020 at manufacturer request. It is not FDA-approved in the United States, where it is sold only as an unapproved gray-market research chemical. The related racetam phenylpiracetam is explicitly listed on the WADA Prohibited List as an S6 stimulant; pramiracetam itself is not explicitly named, leaving its status under WADA's 'similar structure/effect' catch-all unresolved.

Profile Prices Testing

Unifiram

Unifiram (DM-232) is a synthetic non-peptide small-molecule nootropic structurally related to sunifiram, though not a racetam itself. It originated from Italian academic research (University of Florence) in the early 2000s and has never progressed beyond preclinical animal studies; it is not an approved or investigational drug in any regulatory database. Unifiram is sold openly by research-chemical vendors as an unregulated laboratory reagent. No human data of any kind exist.

Profile Prices Testing

Pramiracetam

Unifiram

Category

Cognitive

Legal Status

Research Only

Mechanism

Proposed mechanism is based on animal/in-vitro data, not confirmed in humans: pramiracetam significantly increased sodium-dependent high-affinity choline uptake (HACU) into rat hippocampal synaptosomes in vitro, an effect specific to hippocampus (not observed in cerebral cortex or corpus striatum). At 100 mg/kg i.p. it did not alter norepinephrine, dopamine, serotonin, 5-HIAA, or HVA levels in rat brain, suggesting the effect is not mediated via direct monoaminergic action. The hypothesized downstream effect is increased availability of choline as an acetylcholine synthesis precursor in cholinergic terminals; a separate rat study found systemic pramiracetam increased cortical (not hippocampal) nitric oxide synthase activity in a dose-dependent manner.

Preclinical evidence indicates unifiram facilitates AMPA-receptor-mediated neurotransmission without direct receptor binding: in rat hippocampal slices it increased fEPSP amplitude and reversed kynurenic-acid antagonism of NMDA-mediated transmitter release, effects blocked by the AMPA-receptor antagonist NBQX. It also increased acetylcholine release from rat cerebral cortex, suggesting an additional cholinergic component. Radioligand binding assays showed no significant affinity for major central receptors or ion channels, so the specific molecular binding site remains unidentified.

Side Effects

No dedicated human toxicology (LD50/acute overdose) data located
Reviewed human trials did not report serious adverse events in abstracts (full safety data not independently verified)

Where Researchers Are Buying

Live · updated daily

COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower

Pramiracetam

No pricing data yet.

Check Pramiracetam prices →

Unifiram

Best $/mg

$0.032/mg

Kimera ChemsC

1 trusted vendor listing

Compare all 1 vendor

Lab Verification

COA corpus from Disclosed Labs — independently tested batches only.

Pramiracetam

COAs

99.9%

Avg purity

Labs

Full testing data

Unifiram

COAs

99.4%

Avg purity

Labs

Full testing data

Pramiracetam Research Summary

Human data consist of a handful of small older trials (1985–1996): healthy-volunteer pharmacokinetic studies, a scopolamine-induced-amnesia challenge study, a placebo-controlled trial in young males with head-injury/anoxia-related memory deficits (400 mg TID improved delayed recall), and a small dose-finding trial in Alzheimer's disease that found no convincing benefit at doses up to 4,000 mg. A scopolamine-challenge study (600 mg BID × 10 days) showed partial mitigation of induced amnesia in healthy young and older male volunteers. No modern (post-2000) randomized controlled trials were located. Preclinical findings: in rats, 7.5 and 15 mg/kg/day × 7 weeks significantly improved reference (long-term) memory on a 16-arm radial maze but did not affect working memory; 300 mg/kg i.p. increased cortical nitric oxide synthase activity ~20% (synergistic ~40% increase with lithium pretreatment); moderate protection against hypobaric-hypoxia-induced deficits in immature rats.

Key references

Unifiram Research Summary

No human data of any kind exist for unifiram; no registered clinical trials or published human studies were found. All available evidence is from rodent behavioral and in-vitro electrophysiology studies. In mice and rats, unifiram (0.001–1 mg/kg i.p. or 0.01–0.1 mg/kg oral) reversed amnesia induced by scopolamine, mecamylamine, baclofen, clonidine, and NBQX in passive-avoidance and Morris water-maze tests, at doses roughly 1,000-fold lower than piracetam, without impairing motor coordination or altering spontaneous locomotor activity. No systematic toxicology (repeat-dose, genotoxicity, carcinogenicity) studies have been published.

Key references

Can you stack Pramiracetam and Unifiram?

Pramiracetam and Unifiram are both in the Cognitive category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.

Other comparisons

Piracetam vs Pramiracetam Piracetam vs Unifiram Aniracetam vs Pramiracetam Aniracetam vs Unifiram Oxiracetam vs Pramiracetam Oxiracetam vs Unifiram Nefiracetam vs Pramiracetam Coluracetam vs Pramiracetam

This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.